These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 25746592)

  • 41. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
    Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
    Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
    Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
    Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers.
    Li Z; Zhang Y; Jin T; Men J; Lin Z; Qi P; Piao Y; Yan G
    BMC Cancer; 2015 Mar; 15():207. PubMed ID: 25880877
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
    Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
    Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
    J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FHIT, EGFR, and MSH2: possible etiopathologic, prognostic, and predictive role in non-small cell lung carcinoma in Egyptian patients.
    Younes SF; Aiad HA; Asaad NY; Kandil MA; Natkunam Y; Mokhtar NM
    Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):275-83. PubMed ID: 24185125
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic value of microRNA expression in operable non-small cell lung cancer patients.
    Skrzypski M; Czapiewski P; Goryca K; Jassem E; Wyrwicz L; Pawłowski R; Rzyman W; Biernat W; Jassem J
    Br J Cancer; 2014 Feb; 110(4):991-1000. PubMed ID: 24448358
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long noncoding RNA VPS9D1-AS1 overexpression predicts a poor prognosis in non-small cell lung cancer.
    Tan J; Yang L
    Biomed Pharmacother; 2018 Oct; 106():1600-1606. PubMed ID: 30119235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MicroRNA-153 expression and prognosis in non-small cell lung cancer.
    Chen WJ; Zhang EN; Zhong ZK; Jiang MZ; Yang XF; Zhou DM; Wang XW
    Int J Clin Exp Pathol; 2015; 8(7):8671-5. PubMed ID: 26339455
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor--an expression in non-small-cell lung cancer.
    Huang CL; Liu D; Nakano J; Ishikawa S; Kontani K; Yokomise H; Ueno M
    J Clin Oncol; 2005 Dec; 23(34):8765-73. PubMed ID: 16314637
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Elevated serum apolipoprotein E is associated with metastasis and poor prognosis of non-small cell lung cancer.
    Luo J; Song J; Feng P; Wang Y; Long W; Liu M; Li L
    Tumour Biol; 2016 Aug; 37(8):10715-21. PubMed ID: 26873483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinicopathological significance of fibroblast growth factor 1 in non-small cell lung cancer.
    Li J; Wei Z; Li H; Dang Q; Zhang Z; Wang L; Gao W; Zhang P; Yang D; Liu J; Sun Y; Gao W
    Hum Pathol; 2015 Dec; 46(12):1821-8. PubMed ID: 26391572
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.
    Lebanony D; Benjamin H; Gilad S; Ezagouri M; Dov A; Ashkenazi K; Gefen N; Izraeli S; Rechavi G; Pass H; Nonaka D; Li J; Spector Y; Rosenfeld N; Chajut A; Cohen D; Aharonov R; Mansukhani M
    J Clin Oncol; 2009 Apr; 27(12):2030-7. PubMed ID: 19273703
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification.
    Díaz-García CV; Agudo-López A; Pérez C; López-Martín JA; Rodríguez-Peralto JL; de Castro J; Cortijo A; Martínez-Villanueva M; Iglesias L; García-Carbonero R; Fresno Vara JA; Gámez-Pozo A; Palacios J; Cortés-Funes H; Paz-Ares L; Agulló-Ortuño MT
    Carcinogenesis; 2013 May; 34(5):1031-8. PubMed ID: 23349018
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.
    Chen X; Xu Y; Liao X; Liao R; Zhang L; Niu K; Li T; Li D; Chen Z; Duan Y; Sun J
    Tumour Biol; 2016 Sep; 37(9):11927-11936. PubMed ID: 27075472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation.
    Choi CM; Kim MY; Hwang HJ; Lee JB; Kim WS
    Radiology; 2015 Apr; 275(1):272-9. PubMed ID: 25575117
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC).
    Liu YZ; Jiang YY; Hao JJ; Lu SS; Zhang TT; Shang L; Cao J; Song X; Wang BS; Cai Y; Zhan QM; Wang MR
    Lung Cancer; 2012 Jul; 77(1):176-82. PubMed ID: 22456526
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligands in non-small cell lung carcinoma patients.
    Haghgoo SM; Khosravi A; Mortaz E; Pourabdollah-Toutkaboni M; Seifi S; Sabour S; Allameh A
    Clin Biochem; 2017 Apr; 50(6):293-300. PubMed ID: 27923629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.